Researchers are increasingly focused on retatrutide, a novel treatment from Eli Lilly, as a significant advance in body reduction . Distinct from many earlier approaches, retatrutide is a double -action agonist targeting equally GLP-1 and GIP, substances that influence appetite and blood sugar ba… Read More